PMID- 11010607
OWN - NLM
STAT- MEDLINE
DCOM- 20000915
LR  - 20220330
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 18
IP  - 1
DP  - 2000 Jul
TI  - Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A 
      French sub-study of the ESSENCE trial.
PG  - 83-9
AB  - OBJECTIVES: To perform an evaluation from the societal perspective of the cost of 
      treatment with enoxaparin sodium versus unfractionated heparin (UFH) in patients 
      with unstable angina and non-Q wave myocardial infarction in France. DESIGN: Four 
      complementary cost-minimisation analyses based on the results of the Efficacy and 
      Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events (ESSENCE) 
      international trial were conducted. We assessed differences in medical resource 
      consumption and in duration of hospital stay in the whole study population (n = 
      3171) and for the French patients (n = 133). RESULTS: Results were consistent for 
      the study group as a whole and for the French subgroup. Among patients treated 
      with enoxaparin sodium, there was a statistically significant reduction in the 
      use of angiography and percutaneous transluminal coronary angioplasty (whole 
      group study: p = 0.024 and 0.006, respectively) and a trend towards shorter 
      lengths of hospital stay. The differences in angiography and angioplasty rates 
      led to estimated average net cost savings with enoxaparin sodium of French Francs 
      (FF)1555 per treated patient (whole study population) and FF9993 (French 
      subgroup) [1996 values]. The analyses based on the duration of hospital stay 
      resulted in estimated net cost savings with enoxaparin sodium of between FF1014 
      per treated patient (whole study population) and FF2804 (French subgroup). 
      CONCLUSION: Our study confirmed earlier results which show that enoxaparin sodium 
      is cost saving in the treatment of unstable angina.
FAU - Detournay, B
AU  - Detournay B
AD  - Health Economics Department, CEMKA, Bourg-la-Reine, France. 
      bruno.detournay@cemka.fr
FAU - Huet, X
AU  - Huet X
FAU - Fagnani, F
AU  - Fagnani F
FAU - Montalescot, G
AU  - Montalescot G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 9005-49-6 (Heparin)
MH  - Angina, Unstable/complications/*drug therapy/*economics
MH  - Anticoagulants/*economics/*therapeutic use
MH  - Cost-Benefit Analysis
MH  - Enoxaparin/*economics/*therapeutic use
MH  - France
MH  - Heparin/*economics/*therapeutic use
MH  - Humans
EDAT- 2000/09/30 11:00
MHDA- 2000/09/30 11:01
CRDT- 2000/09/30 11:00
PHST- 2000/09/30 11:00 [pubmed]
PHST- 2000/09/30 11:01 [medline]
PHST- 2000/09/30 11:00 [entrez]
AID - 10.2165/00019053-200018010-00009 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2000 Jul;18(1):83-9. doi: 10.2165/00019053-200018010-00009.